Summary

Triple-negative breast cancer is a heterogeneous disease and therefore presents treatment challenges, as targetable characteristic molecular abnormalities have not yet been identified. As with BRCA1-associated breast cancer, defective DNA repair and homologous recombination are implicated in sporadic TNBC, engendering sensitivity to platinum chemotherapy and poly (ADP-ribose) polymerase.